Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant

Meiyun Fan, Pearlly S. Yan, Cori Hartman-Frey, Lei Chen, Henry Paik, Samuel L. Oyer, Jonathan D. Salisbury, Alfred S.L. Cheng, Lang Li, Phillip H. Abbosh, Tim H.M. Huang, Kenneth P. Nephew

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular characteristics. To further elucidate the molecular events underlying acquired resistance to the antiestrogens tamoxifen and fulvestrant, we established drug-resistant sublines from a single colony of hormone-dependent breast cancer MCF7 cells. These model systems allowed us to examine the cellular and molecular changes induced by antiestrogens in the context of a uniform clonal background. Global changes in both basal and estrogen-induced gene expression profiles were determined in hormone-sensitive and hormonal-resistant sublines using Affymetrix Human Genome U133 Plus 2.0 Arrays. Changes in DNA methylation were assessed by differential methylation hybridization, a high-throughput promoter CpG island microarray analysis. By comparative studies, we found distinct gene expression and promoter DNA methylation profiles associated with acquired resistance to fulvestrant versus tamoxifen. Fulvestrant resistance was characterized by pronounced upregulation of multiple growth-stimulatory pathways, resulting in estrogen receptor α (FRα)-independent, autocrine-regulated proliferation. Conversely, acquired resistance to tamoxifen correlated with maintenance of the ERα-positive phenotype, although receptor-mediated gene regulation was altered. Activation of growth-promoting genes, due to promoter hypomethylation, was more frequently observed in antiestrogen-resistant cells compared with gene inactivation by promoter hypermethylation, revealing an unexpected insight into the molecular changes associated with endocrine resistance. In summary, this study provides an in-depth understanding of the molecular changes specific to acquired resistance to clinically important antiestrogens. Such knowledge of resistance-associated mechanisms could allow for identification of therapy targets and strategies for resensitization to these well-established antihormonal agents.

Original languageEnglish (US)
Pages (from-to)11954-11966
Number of pages13
JournalCancer Research
Volume66
Issue number24
DOIs
StatePublished - Dec 15 2006

Fingerprint

Estrogen Receptor Modulators
DNA Methylation
Tamoxifen
Breast Neoplasms
Gene Expression
Hormones
CpG Islands
MCF-7 Cells
Gene Silencing
Human Genome
Microarray Analysis
Growth
Transcriptome
Estrogen Receptors
Methylation
Genes
Estrogens
Up-Regulation
Maintenance
fulvestrant

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. / Fan, Meiyun; Yan, Pearlly S.; Hartman-Frey, Cori; Chen, Lei; Paik, Henry; Oyer, Samuel L.; Salisbury, Jonathan D.; Cheng, Alfred S.L.; Li, Lang; Abbosh, Phillip H.; Huang, Tim H.M.; Nephew, Kenneth P.

In: Cancer Research, Vol. 66, No. 24, 15.12.2006, p. 11954-11966.

Research output: Contribution to journalArticle

Fan, M, Yan, PS, Hartman-Frey, C, Chen, L, Paik, H, Oyer, SL, Salisbury, JD, Cheng, ASL, Li, L, Abbosh, PH, Huang, THM & Nephew, KP 2006, 'Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant', Cancer Research, vol. 66, no. 24, pp. 11954-11966. https://doi.org/10.1158/0008-5472.CAN-06-1666
Fan, Meiyun ; Yan, Pearlly S. ; Hartman-Frey, Cori ; Chen, Lei ; Paik, Henry ; Oyer, Samuel L. ; Salisbury, Jonathan D. ; Cheng, Alfred S.L. ; Li, Lang ; Abbosh, Phillip H. ; Huang, Tim H.M. ; Nephew, Kenneth P. / Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. In: Cancer Research. 2006 ; Vol. 66, No. 24. pp. 11954-11966.
@article{61182ae950fd4f418889a660bffa76a7,
title = "Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant",
abstract = "The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular characteristics. To further elucidate the molecular events underlying acquired resistance to the antiestrogens tamoxifen and fulvestrant, we established drug-resistant sublines from a single colony of hormone-dependent breast cancer MCF7 cells. These model systems allowed us to examine the cellular and molecular changes induced by antiestrogens in the context of a uniform clonal background. Global changes in both basal and estrogen-induced gene expression profiles were determined in hormone-sensitive and hormonal-resistant sublines using Affymetrix Human Genome U133 Plus 2.0 Arrays. Changes in DNA methylation were assessed by differential methylation hybridization, a high-throughput promoter CpG island microarray analysis. By comparative studies, we found distinct gene expression and promoter DNA methylation profiles associated with acquired resistance to fulvestrant versus tamoxifen. Fulvestrant resistance was characterized by pronounced upregulation of multiple growth-stimulatory pathways, resulting in estrogen receptor α (FRα)-independent, autocrine-regulated proliferation. Conversely, acquired resistance to tamoxifen correlated with maintenance of the ERα-positive phenotype, although receptor-mediated gene regulation was altered. Activation of growth-promoting genes, due to promoter hypomethylation, was more frequently observed in antiestrogen-resistant cells compared with gene inactivation by promoter hypermethylation, revealing an unexpected insight into the molecular changes associated with endocrine resistance. In summary, this study provides an in-depth understanding of the molecular changes specific to acquired resistance to clinically important antiestrogens. Such knowledge of resistance-associated mechanisms could allow for identification of therapy targets and strategies for resensitization to these well-established antihormonal agents.",
author = "Meiyun Fan and Yan, {Pearlly S.} and Cori Hartman-Frey and Lei Chen and Henry Paik and Oyer, {Samuel L.} and Salisbury, {Jonathan D.} and Cheng, {Alfred S.L.} and Lang Li and Abbosh, {Phillip H.} and Huang, {Tim H.M.} and Nephew, {Kenneth P.}",
year = "2006",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-06-1666",
language = "English (US)",
volume = "66",
pages = "11954--11966",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant

AU - Fan, Meiyun

AU - Yan, Pearlly S.

AU - Hartman-Frey, Cori

AU - Chen, Lei

AU - Paik, Henry

AU - Oyer, Samuel L.

AU - Salisbury, Jonathan D.

AU - Cheng, Alfred S.L.

AU - Li, Lang

AU - Abbosh, Phillip H.

AU - Huang, Tim H.M.

AU - Nephew, Kenneth P.

PY - 2006/12/15

Y1 - 2006/12/15

N2 - The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular characteristics. To further elucidate the molecular events underlying acquired resistance to the antiestrogens tamoxifen and fulvestrant, we established drug-resistant sublines from a single colony of hormone-dependent breast cancer MCF7 cells. These model systems allowed us to examine the cellular and molecular changes induced by antiestrogens in the context of a uniform clonal background. Global changes in both basal and estrogen-induced gene expression profiles were determined in hormone-sensitive and hormonal-resistant sublines using Affymetrix Human Genome U133 Plus 2.0 Arrays. Changes in DNA methylation were assessed by differential methylation hybridization, a high-throughput promoter CpG island microarray analysis. By comparative studies, we found distinct gene expression and promoter DNA methylation profiles associated with acquired resistance to fulvestrant versus tamoxifen. Fulvestrant resistance was characterized by pronounced upregulation of multiple growth-stimulatory pathways, resulting in estrogen receptor α (FRα)-independent, autocrine-regulated proliferation. Conversely, acquired resistance to tamoxifen correlated with maintenance of the ERα-positive phenotype, although receptor-mediated gene regulation was altered. Activation of growth-promoting genes, due to promoter hypomethylation, was more frequently observed in antiestrogen-resistant cells compared with gene inactivation by promoter hypermethylation, revealing an unexpected insight into the molecular changes associated with endocrine resistance. In summary, this study provides an in-depth understanding of the molecular changes specific to acquired resistance to clinically important antiestrogens. Such knowledge of resistance-associated mechanisms could allow for identification of therapy targets and strategies for resensitization to these well-established antihormonal agents.

AB - The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular characteristics. To further elucidate the molecular events underlying acquired resistance to the antiestrogens tamoxifen and fulvestrant, we established drug-resistant sublines from a single colony of hormone-dependent breast cancer MCF7 cells. These model systems allowed us to examine the cellular and molecular changes induced by antiestrogens in the context of a uniform clonal background. Global changes in both basal and estrogen-induced gene expression profiles were determined in hormone-sensitive and hormonal-resistant sublines using Affymetrix Human Genome U133 Plus 2.0 Arrays. Changes in DNA methylation were assessed by differential methylation hybridization, a high-throughput promoter CpG island microarray analysis. By comparative studies, we found distinct gene expression and promoter DNA methylation profiles associated with acquired resistance to fulvestrant versus tamoxifen. Fulvestrant resistance was characterized by pronounced upregulation of multiple growth-stimulatory pathways, resulting in estrogen receptor α (FRα)-independent, autocrine-regulated proliferation. Conversely, acquired resistance to tamoxifen correlated with maintenance of the ERα-positive phenotype, although receptor-mediated gene regulation was altered. Activation of growth-promoting genes, due to promoter hypomethylation, was more frequently observed in antiestrogen-resistant cells compared with gene inactivation by promoter hypermethylation, revealing an unexpected insight into the molecular changes associated with endocrine resistance. In summary, this study provides an in-depth understanding of the molecular changes specific to acquired resistance to clinically important antiestrogens. Such knowledge of resistance-associated mechanisms could allow for identification of therapy targets and strategies for resensitization to these well-established antihormonal agents.

UR - http://www.scopus.com/inward/record.url?scp=33846207899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846207899&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1666

DO - 10.1158/0008-5472.CAN-06-1666

M3 - Article

VL - 66

SP - 11954

EP - 11966

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -